Skip to main content

Table 3 Spearman's rank correlation coefficient of PVF BW in comparison with measures a

From: Clinical validity of outcome pain measures in naturally occurring canine osteoarthritis

Comparison of PVFBW with: n D0 (95% CI) D30 (95% CI) D90 (95% CI) Difference D0D30 (95% CI) Difference D30D90 (95% CI)
Primary endpoints       
CSOM 23 -.03 (−.64, .32) .10 (−.38, .57) -.37 (−.74, .12) .13 (−.44, .66) -.71 (−.91, -.34)
EDA 23 -.23 (−.61, .24) .10 (−.44, .60) .16 (−.36, .62) -.12 (−.60, .43) .31 (−.23, .69)
Exploratory endpoints       
MA 7 -.46 (−1.0, .77) .10 (−1.0, 1.0) .45 (−.68, 1.0) -.04 (−.94, 1.0) .14 (−1.0, 0.80)
Ctg(1) 20 -.20 (−.65, .42) -.29 (−.66, .21) -.13 (−.58, .40) -.03 (−.67, .74) -.64 (−.87, -.15)
Ctg(2) 10 .01 (−.77, .78) .00 (−.77, .79) -.75 (−1.0, 0.00) -.03 (−.81, .74) -.52 (−.90, .45)
Ctg(3) 9 .56 (−.72, 1.0) .54 (−.31, 1.0) .52 (−.81, 1.0) .00 (−.91, .92) -.99 (−1.0, -.87)
Ctg(4) 8 .20 (−.44, .94) .09 (−.91, 1.0) .07 (−.91, 1.0) .20 (−.94, 1.0) -.66 (−1.0, .71)
  1. PVF BW : peak vertical ground reaction force adjusted for body weight change.
  2. aCSOM: client-specific outcome measures; EDA: electrodermal activity; MA: motor activity; Ctg (1) : Reduced mobility; Ctg (2) : Reduced mobility after exercise; Ctg (3) : Reduced ability to change posture; Ctg (4) : Reduced ability to change posture after rest or in the morning.
  3. Descriptive data are represented as Spearman's rank correlation coefficient at day(D)0, D30, D90, difference between D0 and D30 (D0D30), and difference between D30 and D90 (D30D90). 95% CI: 95% confidence interval from bootstrap method of sample of n dogs (1000 samples randomly selected with replacement). NA: not available.